<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We analysed the impact of age and gender on biology and outcome of 2084 patients diagnosed with non-Hodgkin <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (NHL) between October 1986 and December 2002 and treated according to the Berlin-Frankfurt-MÃ¼nster (BFM) multicentre protocols NHL-BFM-86, -90 and -95 </plain></SENT>
<SENT sid="1" pm="."><plain>Median age at diagnosis was 8.0 years for 97 precursor B-lymphoblastic <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (pB-LBL) patients, 8.8 years for 335 T-lymphoblastic <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (T-LBL) patients, 8.4 years for 1004 Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo>/<z:mpath ids='MPATH_336'>leukaemia</z:mpath> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>/B-AL) patients, 11.4 years for 173 diffuse large B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="C1516391" disease_type="Neoplastic Process" abbrv="">centroblastic</z:e> subtype) (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e>-CB) patients, 13.2 years for 40 primary mediastinal large B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (PMLBL) patients and 10.8 years for 215 anaplastic large-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ALCL</z:e>) patients (P &lt; 0.00001) </plain></SENT>
<SENT sid="2" pm="."><plain>The male:female ratio was 0.9:1 for pB-LBL and PMLBL, 1.7:1 for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e>-CB, 1.8:1 for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ALCL</z:e>, 2.5:1 for T-LBL and 4.5:1 for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>/B-AL (P &lt; 0.00001) </plain></SENT>
<SENT sid="3" pm="."><plain>The probability of event-free survival at 5 years (5-year pEFS) was 85 +/- 1% for <z:hpo ids='HP_0000001'>all</z:hpo> 2084 patients [median follow-up 5.7 (0.1-15.9) years], and was significantly superior for male T-LBL and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e>-CB patients </plain></SENT>
<SENT sid="4" pm="."><plain>Comparing age-groups 0-4, 5-9, 10-14 and 15-18 years, pEFS was inferior for the youngest patients only in the pB-LBL- and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ALCL</z:e>-groups </plain></SENT>
<SENT sid="5" pm="."><plain>T-LBL and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e>-CB adolescent females had worse outcome than younger girls while age had no impact on pEFS for boys </plain></SENT>
<SENT sid="6" pm="."><plain>We conclude that the distribution of age and gender differed between NHL-subtypes </plain></SENT>
<SENT sid="7" pm="."><plain>The impact of gender on outcome differed between NHL subgroups </plain></SENT>
<SENT sid="8" pm="."><plain>The prognostic impact of age differed not only by NHL-subtype but also according to gender in some subtypes </plain></SENT>
</text></document>